The Use of Quinacrine in Nitroimidazole-resistant Giardia Duodenalis: An Old Drug for an Emerging Problem.
Resumen: Background:
There is little evidence regarding the management of refractory giardiasis after treatment with nitroimidazoles. This study estimates the proportion of persistent giardiasis in 3 hospitals in Barcelona, describes associated risk factors and genotype, and evaluates the efficacy rate of quinacrine in those with persistent giardiasis.
A clinical, prospective, observational study was conducted in patients with giardiasis treated with nitroimidazoles. Those with persistent giardiasis were provided quinacrine. Molecular characterization of Giardia isolates was performed by polymerase chain reaction amplification of a fragment of tpi and bg genes.
Seventy-seven patients were recruited and treated with nitroimidazoles, and in 14 of 71 (20%) of patients followed up, Giardia persisted. Refractory giardiasis was associated with malaise (P = .007) and anorexia (P = .02), with previous giardiasis (P = .03), and with previous antibiotic (P = .02) or antiparasitic(P = .04) use. Quinacrine had an effectiveness rate of 100% in refractory giardiasis (n = 13; 95% confidence interval = 75-100). Molecular characterization showed that 17 (25%) Giardia isolates belonged to assemblage A, and 31 (43%) belonged to assemblage B. In refractory giardiasis, assemblage A and B were found responsible in 4 and 6 cases, respectively.
Almost 20% of patients presented persistent giardiasis, belonging to both assemblages A and B, after nitroimidazole. Short course of quinacrine was effective in treating refractory cases. Further controlled studies should evaluate its efficacy and safety.

Idioma: Inglés
DOI: 10.1093/infdis/jix066
Año: 2017
Publicado en: JOURNAL OF INFECTIOUS DISEASES 215, 6 (2017), 946-953
ISSN: 0022-1899

Factor impacto JCR: 5.186 (2017)
Categ. JCR: IMMUNOLOGY rank: 35 / 155 = 0.226 (2017) - Q1 - T1
Categ. JCR: MICROBIOLOGY rank: 20 / 125 = 0.16 (2017) - Q1 - T1
Categ. JCR: INFECTIOUS DISEASES rank: 9 / 88 = 0.102 (2017) - Q1 - T1

Factor impacto SCIMAGO: 3.302 - Infectious Diseases (Q1) - Immunology and Allergy (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B124
Financiación: info:eu-repo/grantAgreement/ES/MINECO/FIS/PI09-1585
Tipo y forma: Article (Published version)
Área (Departamento): Área Parasitología (Dpto. Microb.Med.Pr.,Sal.Públ.)
Área (Departamento): Área Medic.Prevent.Salud Públ. (Dpto. Microb.Med.Pr.,Sal.Públ.)

Rights Reserved All rights reserved by journal editor

Exportado de SIDERAL (2019-08-19-09:51:50)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2017-05-22, last modified 2019-08-19

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)